Justin Walsh
Stock Analyst at Jones Trading
(3.46)
# 977
Out of 5,182 analysts
40
Total ratings
48.65%
Success rate
26.29%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $49 → $44 | $24.47 | +79.81% | 2 | Apr 2, 2026 | |
| NMTC NeuroOne Medical Technologies | Initiates: Buy | $9 | $4.75 | +89.47% | 1 | Mar 2, 2026 | |
| LNTH Lantheus Holdings | Downgrades: Hold | n/a | $83.55 | - | 11 | Feb 27, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $16 | $4.33 | +269.52% | 1 | Dec 23, 2025 | |
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $321.92 | -74.22% | 1 | Sep 18, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $2.78 | +7.91% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $2.63 | +356.27% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $5.85 | +412.82% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $54.48 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $1.85 | +494.59% | 1 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $33.74 | +24.48% | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $3.95 | +456.96% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.49 | +256.35% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.27 | +368.38% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.60 | +566.67% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.69 | +442.01% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $14.38 | +2,403.48% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $5.95 | +31,412.61% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $40.48 | -50.59% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $0.58 | +34,258.36% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.84 | +443.48% | 1 | Jan 19, 2022 |
Alto Neuroscience
Apr 2, 2026
Maintains: Buy
Price Target: $49 → $44
Current: $24.47
Upside: +79.81%
NeuroOne Medical Technologies
Mar 2, 2026
Initiates: Buy
Price Target: $9
Current: $4.75
Upside: +89.47%
Lantheus Holdings
Feb 27, 2026
Downgrades: Hold
Price Target: n/a
Current: $83.55
Upside: -
AtaiBeckley
Dec 23, 2025
Initiates: Buy
Price Target: $16
Current: $4.33
Upside: +269.52%
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $321.92
Upside: -74.22%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $2.78
Upside: +7.91%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $2.63
Upside: +356.27%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $5.85
Upside: +412.82%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $54.48
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $1.85
Upside: +494.59%
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $33.74
Upside: +24.48%
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $3.95
Upside: +456.96%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $4.49
Upside: +256.35%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.27
Upside: +368.38%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.60
Upside: +566.67%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.69
Upside: +442.01%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $14.38
Upside: +2,403.48%
Oct 7, 2022
Initiates: Buy
Price Target: $1,875
Current: $5.95
Upside: +31,412.61%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $40.48
Upside: -50.59%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $0.58
Upside: +34,258.36%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $1.84
Upside: +443.48%